(19)
(11) EP 2 960 233 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.12.2019 Bulletin 2019/49

(45) Mention of the grant of the patent:
30.10.2019 Bulletin 2019/44

(21) Application number: 15174854.8

(22) Date of filing: 25.06.2009
(51) International Patent Classification (IPC): 
C07D 209/48(2006.01)
C07D 403/06(2006.01)
A61P 35/00(2006.01)
 C07D 401/06(2006.01)
A61K 31/4035(2006.01)

(54)

NEW THERAPEUTIC AGENTS

NEUARTIGE THERAPEUTIKA

NOUVEAUX AGENTS THÉRAPEUTIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 25.06.2008 GB 0811643

(43) Date of publication of application:
30.12.2015 Bulletin 2015/53

(62) Application number of the earlier application in accordance with Art. 76 EPC:
09769576.1 / 2315749

(73) Proprietor: Cancer Research Technology Limited
London E20 1JQ (GB)

(72) Inventors:
  • GOLDING, Bernard, Thomas
    Newcastle upon Tyne, NE27 OEZ (GB)
  • RIEDINGER, Christiane
    Oxford, OX2 0HT (GB)
  • GRIFFIN, Roger John
    Northumberland, NE61 3SZ (GB)
  • HARDCASTLE, Ian, Robert
    Hexham, NE46 3JP (GB)
  • VALEUR, Eric
    42674 Vastra Frolunda (SE)
  • WATSON, Anna, Frances
    Canterbury, CT29DG (GB)
  • NOBLE, Martin
    Oxford, OX1J3QU (GB)

(74) Representative: Elkington and Fife LLP 
Prospect House 8 Pembroke Road
Sevenoaks, Kent TN13 1XR
Sevenoaks, Kent TN13 1XR (GB)


(56) References cited: : 
WO-A-2006/024837
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).